Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA: 688266)

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2,320	2,110	797.05	1,137	1,150	66.92
Trading Asset Securities	56.23	137.02	248.93	65.26	449.85	6
Cash & Short-Term Investments	2,377	2,247	1,046	1,202	1,600	72.92
Cash Growth	6.86%	114.79%	-12.97%	-24.86%	2093.61%	-65.53%
Accounts Receivable	130.88	101.14	88.99	62.37	-	-
Other Receivables	9.36	10.89	12.51	12.45	2.62	7.03
Receivables	140.24	112.03	101.5	74.82	2.62	7.03
Inventory	141.12	110.85	98.98	51.91	23.14	6.43
Prepaid Expenses	-	-	-	-	0.39	-
Other Current Assets	47.87	50.79	45.3	77.33	43.83	15.45
Total Current Assets	2,706	2,520	1,292	1,406	1,670	101.82
Property, Plant & Equipment	293.85	271.21	247.09	188.91	91.03	56.67
Long-Term Investments	5.99	5.99	10	10	10	-
Other Intangible Assets	59.52	69.27	91.03	116.29	129.51	135.81
Long-Term Deferred Charges	28.75	16.39	20.96	13.03	4.35	0.87
Other Long-Term Assets	5.82	4.02	7.48	11.78	65.82	25.1
Total Assets	3,100	2,887	1,668	1,746	1,970	320.27
Accounts Payable	128.86	137.73	151.72	118.19	64.96	54.03
Accrued Expenses	67.74	74.96	67.5	48.22	30.92	16.57
Short-Term Debt	914.21	795.16	390.79	131.81	17.67	60
Current Portion of Long-Term Debt	-	50.56	50.04	30.03	-	-
Current Portion of Leases	13.17	13.17	13.69	13.55	-	-
Current Income Taxes Payable	20.77	20.64	20.29	18.58	16.94	11.45
Current Unearned Revenue	-	-	0.28	0.36	-	-
Other Current Liabilities	24.39	42.95	34.88	20.16	10.38	8.11
Total Current Liabilities	1,169	1,135	729.19	380.89	140.88	150.17
Long-Term Debt	-	-	50.09	-	30.03	-
Long-Term Leases	29.18	29.46	43.18	48.18	4.32	4.83
Long-Term Unearned Revenue	14.02	11.55	45.04	48.05	83.66	66.22
Long-Term Deferred Tax Liabilities	7.65	9.58	13.32	15.77	19.81	25.3
Other Long-Term Liabilities	311.32	56.6	-	-	-	-
Total Liabilities	1,531	1,242	880.82	492.88	278.69	246.52
Common Stock	264.71	264.71	240	240	240	180
Additional Paid-In Capital	3,353	3,353	2,222	2,205	2,174	294.98
Retained Earnings	-2,045	-1,979	-1,700	-1,243	-791.56	-472.33
Comprensive Income & Other	-5.66	-5.95	-2.84	-6.32	-5.04	0.77
Total Common Equity	1,567	1,633	759.12	1,196	1,618	3.43
Minority Interest	1.32	11.98	28.37	56.76	73.86	70.32
Shareholders' Equity	1,568	1,645	787.49	1,253	1,692	73.75
Total Liabilities & Equity	3,100	2,887	1,668	1,746	1,970	320.27
Total Debt	956.56	888.35	547.8	223.57	52.02	64.83
Net Cash (Debt)	1,420	1,358	498.18	978.32	1,548	8.09
Net Cash Growth	-3.44%	172.65%	-49.08%	-36.78%	19021.89%	-96.09%
Net Cash Per Share	5.37	5.31	2.08	4.08	6.59	0.05
Filing Date Shares Outstanding	264.71	264.71	264.49	240	240	240
Total Common Shares Outstanding	264.71	264.71	240	240	240	180
Working Capital	1,537	1,385	562.57	1,025	1,529	-48.34
Book Value Per Share	5.92	6.17	3.16	4.98	6.74	0.02
Tangible Book Value	1,508	1,564	668.09	1,080	1,488	-132.38
Tangible Book Value Per Share	5.70	5.91	2.78	4.50	6.20	-0.74
Buildings	41.93	41.93	41.93	41.21	-	40.92
Machinery	143.04	125.42	121.74	96.02	-	32.59
Construction In Progress	146.91	135.83	86.67	27.25	-	0.55

Source: S&P Capital IQ. Standard template. Financial Sources.